Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
39
YMAB Quote, Financials, Valuation and Earnings
Last price:
$3.88
Seasonality move
:
13.57%
Day range:
$3.87 - $4.26
52-week range:
$3.76 - $16.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.97x
P/B ratio:
1.91x
Volume:
444.2K
Avg. volume:
257.1K
1-year change:
-69.77%
Market cap:
$176.1M
Revenue:
$87.7M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingY-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $16.10, Y-mAbs Therapeutics has an estimated upside of 313.88% from its current price of $3.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $3.89.
Fair Value
-
According to the consensus of 8 analysts, Y-mAbs Therapeutics has 313.88% upside to fair value with a price target of $16.10 per share.
YMAB vs. S&P 500
-
Over the past 5 trading days, Y-mAbs Therapeutics has underperformed the S&P 500 by -11.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Y-mAbs Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Y-mAbs Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Y-mAbs Therapeutics reported revenues of $26.5M.
Earnings Growth
-
Y-mAbs Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Y-mAbs Therapeutics reported earnings per share of -$0.15.
Enterprise value:
108.9M
EV / Invested capital:
--
Price / LTM sales:
1.97x
EV / EBIT:
--
EV / Revenue:
1.24x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-6.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$72.4M
Return On Assets:
-23.32%
Net Income Margin (TTM):
-33.83%
Return On Equity:
-30.91%
Return On Invested Capital:
-30.91%
Operating Margin:
-22.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $65.3M | $84.8M | $87.7M | $23.4M | $26.5M | |
| Gross Profit | $57.7M | $73.4M | $72.4M | $21.3M | $18.7M | |
| Operating Income | -$94.8M | -$25.7M | -$31.2M | -$3.2M | -$5.9M | |
| EBITDA | -$94M | -$24.9M | -$30.7M | -$3M | -$5.8M | |
| Diluted EPS | -$2.18 | -$0.49 | -$0.67 | -$0.02 | -$0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $122.4M | $202.3M | $130.4M | $111.1M | $98.5M | |
| Total Assets | $132M | $212.8M | $141.5M | $127.9M | $119.9M | |
| Current Liabilities | $19.5M | $27.9M | $28.3M | $20.1M | $23.7M | |
| Total Liabilities | $26.2M | $32.7M | $32.2M | $26.9M | $27.9M | |
| Total Equity | $105.8M | $180.1M | $109.2M | $101M | $92M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$75.9M | -$27.2M | -$15.7M | -$8M | -$1.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $84K | $100K | $4.3M | $100K | $986K | |
| Free Cash Flow | -$75.9M | -$27.2M | -$15.7M | -$8M | -$1.9M | |
YMAB
Sector
Market Cap
$176.1M
$33.9M
Price % of 52-Week High
24.15%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-69.78%
-40.43%
Beta (5-Year)
0.531
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.09
200-day SMA
Sell
Level
$9.41
Bollinger Bands (100)
Sell
Level
4.31 - 7.35
Chaikin Money Flow
Buy
Level
3.2M
20-day SMA
Sell
Level
$4.34
Relative Strength Index (RSI14)
Sell
Level
40.45
ADX Line
Sell
Level
15.58
Williams %R
Buy
Level
-84.7953
50-day SMA
Sell
Level
$4.63
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
17M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5089)
Buy
CA Score
(Annual)
Level (-0.0422)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.3838)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Stock Forecast FAQ
In the current month, YMAB has received 7 Buy ratings 0 Hold ratings, and 1 Sell ratings. The YMAB average analyst price target in the past 3 months is $16.10.
-
Where Will Y-mAbs Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Y-mAbs Therapeutics share price will rise to $16.10 per share over the next 12 months.
-
What Do Analysts Say About Y-mAbs Therapeutics?
Analysts are divided on their view about Y-mAbs Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Y-mAbs Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Y-mAbs Therapeutics's Price Target?
The price target for Y-mAbs Therapeutics over the next 1-year time period is forecast to be $16.10 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is YMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Y-mAbs Therapeutics is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of YMAB?
You can purchase shares of Y-mAbs Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Y-mAbs Therapeutics shares.
-
What Is The Y-mAbs Therapeutics Share Price Today?
Y-mAbs Therapeutics was last trading at $3.88 per share. This represents the most recent stock quote for Y-mAbs Therapeutics. Yesterday, Y-mAbs Therapeutics closed at $3.89 per share.
-
How To Buy Y-mAbs Therapeutics Stock Online?
In order to purchase Y-mAbs Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Sell
50
QDEL alert for May 10
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
